Edwards Lifesciences (NYSE:EW) Stock Price Up 0.5%

Edwards Lifesciences Co. (NYSE:EW)’s stock price traded up 0.5% on Friday . The stock traded as high as $88.05 and last traded at $87.88. 340,046 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 3,536,100 shares. The stock had previously closed at $87.46.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Mizuho raised their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research note on Friday, April 26th. Stifel Nicolaus lifted their target price on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Friday, April 26th. StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. Finally, Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $94.31.

Edwards Lifesciences Stock Up 0.6 %

The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The stock has a market cap of $53.02 billion, a price-to-earnings ratio of 37.92, a PEG ratio of 3.20 and a beta of 1.10. The business’s fifty day moving average is $89.68 and its two-hundred day moving average is $81.63.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. Equities analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian purchased 580 shares of the stock in a transaction on Monday, May 6th. The stock was bought at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Bernard J. Zovighian purchased 580 shares of the stock in a transaction on Monday, May 6th. The stock was bought at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The disclosure for this sale can be found here. Over the last quarter, insiders sold 180,707 shares of company stock worth $16,034,814. Corporate insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Crewe Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $28,000. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $34,000. DSM Capital Partners LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $28,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $34,000. Finally, Rise Advisors LLC raised its position in Edwards Lifesciences by 125.0% in the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 265 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.